文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术后延长静脉血栓栓塞预防的趋势

Trends in Extended-Duration Venous Thromboembolism Prophylaxis Following Radical Cystectomy.
PubMed 文献 · Urology · 2019-11-09

该研究基于OptumLabs数据仓库2012至2017年接受根治性膀胱切除术的膀胱癌患者,评估延长药物预防(EDPP)处方趋势。共2054例患者中386例(19%)接受EDPP,处方率从2012年9%升至2017年26%(P<.001)。多因素分析显示年龄<65岁、新辅助化疗、较近手术年份、公立医院、住院医师培训医院或机器人手术医院与EDPP处方增加相关,但仍有少数患者获得EDPP。

要点

  • EDPP处方率从2012年9%升至2017年26%,但仍仅19%患者接受。
  • 年龄<65岁、新辅助化疗及较近手术年份与EDPP处方增加相关。
  • 公立医院、住院医师培训医院或机器人手术医院EDPP处方率更高。

核心结论

  • 根治性膀胱切除术后EDPP处方率随时间增加但仍仅少数患者接受,数据可用于指导质量改进。

研究设计与样本

  • 基于OptumLabs Data Warehouse全国行政索赔数据库,识别2012至2017年因膀胱癌行根治性膀胱切除术的患者2054例。

主要发现

  • 386例(19%)患者接受EDPP处方,处方率从2012年9%显著增至2017年26%(P<.001)。
  • 多因素分析显示年龄<65岁(OR 1.79,95%CI 1.39-2.33;P<.001)与新辅助化疗(OR 1.33,95%CI 1.04-1.71;P=.02)与EDPP处方增加相关。
  • 较近手术年份(OR 4.11,95%CI 2.35-7.18;P<.001)、公立医院(OR 3.38,95%CI 1.31-8.74;P=.01)、住院医师培训医院(OR 4.45,95%CI 1.26-15.7;P=.02)及机器人手术医院(OR 3.44,95%CI 1.31-9.08;P=.01)与EDPP处方增加相关。

临床怎么用

  • 临床应关注根治性膀胱切除术后EDPP处方的质量改进,尤其针对非公立、非教学及非机器人手术医院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate temporal trends in prescriptions for extended-duration pharmacologic prophylaxis (EDPP) intended to prevent venous thromboembolism following radical cystectomy (RC). MATERIALS AND METHODS: We used OptumLabs Data Warehouse, a national administrative claims database, to identify patients undergoing RC for bladder cancer from 2012 to 2017. Rates of outpatient prescriptions for EDPP following RC were assessed, and rate over time was evaluated using the Cochran-Armitage test for trend. Multivariable logistic regression was used to examine associations between clinical and practice-level characteristics with EDPP prescriptions. RESULTS: A total of 2054 patients were identified, including 386 (19%) who received an EDPP prescription. The rate of EDPP prescriptions increased significantly over the study period, from 9% of cases in 2012 to 26% of cases in 2017 (P <.001). On multivariable logistic regression, age <65 (OR 1.79, 95% CI 1.39-2.33; P <.001), receipt of neoadjuvant chemotherapy (OR 1.33, 95% CI 1.04-1.71; P = .02), more recent procedure year (OR 4.11, 95% CI 2.35-7.18; P <.001), treatment in a public as compared to a for-profit hospital (OR 3.38, 95% CI 1.31-8.74; P = .01), and treatment at a hospital with residency training (OR 4.45, 95% CI 1.26-15.7; P = .02) or a surgical robot (OR 3.44, 95% CI 1.31-9.08; P = .01) were significantly associated with increased odds of receiving EDPP. CONCLUSION: EDPP following RC has increased over time, but is still provided for only a minority of patients. These data may be useful for guiding quality improvement efforts given recent literature supporting the use of EDPP.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lyon TD, Shah ND, Tollefson MK, et al. Trends in Extended-Duration Venous Thromboembolism Prophylaxis Following Radical Cystectomy. Urology. 2019. PMID: 31715273. doi:10.1016/j.urology.2019.09.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。